JAZZ : Summary for Jazz Pharmaceuticals plc - Ordi - Yahoo Finance

U.S. Markets closed

Jazz Pharmaceuticals Public Limited Company (JAZZ)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
102.32+0.56 (+0.55%)
At close: 4:00 PM EST
People also watch:
ALXNMDVNREGNBMRNAKRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close101.76
Open101.80
Bid102.32 x 100
Ask126.26 x 100
Day's Range101.80 - 103.40
52 Week Range95.80 - 160.00
Volume512,713
Avg. Volume625,209
Market Cap6.13B
Beta1.34
PE Ratio (TTM)17.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
    Zacks4 days ago

    Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial

    Jazz Pharmaceuticals Public Limited Company (JAZZ) announced that its phase III study, evaluating JZP-110 has completed patient enrollment.

  • PR Newswire5 days ago

    Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy

    DUBLIN, Nov. 28, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in excessive sleepiness (ES) associated with narcolepsy. The Phase 3 narcolepsy study was a double-blind, placebo-controlled, multiple-center study evaluating the safety and efficacy of JZP-110 in the treatment of ES in adult patients with narcolepsy.  The study enrolled 240 patients.  The co-primary endpoints were the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale.  These are validated endpoints, commonly used in clinical trials, that measure the ability to stay awake and the severity of excessive sleepiness, respectively, in patients.

  • Gurus Invest in Undervalued Biotech Stocks
    GuruFocus.com8 days ago

    Gurus Invest in Undervalued Biotech Stocks

    Health care sector moderately undervalued based on price-to-sales valuations